دورية أكاديمية
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates.
| العنوان: | Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. |
|---|---|
| المؤلفون: | Parker JN; Department of Pediatrics, Division of Infectious Diseases, The University of Alabama at Birmingham, CHB 118B, 1600 6th Avenue South, Birmingham, AL 35233, USA. jnparker@uab.edu, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, Whitley RJ |
| المصدر: | Vaccine [Vaccine] 2006 Mar 06; Vol. 24 (10), pp. 1644-52. Date of Electronic Publication: 2005 Oct 05. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0264-410X (Print) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | Granulocyte-Macrophage Colony-Stimulating Factor/*genetics , Herpes Simplex Virus Vaccines/*immunology , Interleukin-12/*genetics , Simplexvirus/*genetics , Vaccines, Synthetic/*immunology, Animals ; Female ; Genetic Engineering ; Herpes Simplex Virus Vaccines/administration & dosage ; Mice ; Mice, Inbred BALB C ; Simplexvirus/pathogenicity ; Simplexvirus/physiology ; Trigeminal Ganglion/virology ; Vaccines, Attenuated/immunology ; Vaccines, Synthetic/administration & dosage ; Virulence ; Virus Activation ; Virus Replication |
| مستخلص: | We are using genetically modified, conditionally replicating herpes simplex virus (HSV) that express either interleukin (IL)-12 or granulocyte macrophage-colony stimulating factor (GM-CSF) as live, attenuated vaccine candidates for protection against HSV infection and/or disease. We report the following: (1) animals previously vaccinated with these candidate vaccines exhibited dose-dependent protection after intranasal, intraperitoneal or intracranial challenge with the highly virulent E377-MB wild-type HSV-1; (2) the IL-12 expressing virus (M002) consistently conferred protection at lower immunization doses than GM-CSF expressing virus (M004); (3) between 80 and 100% protection from E377-MB challenge was conferred after intramuscular immunization of mice with any of the three Deltagamma1 34.5 HSV, as opposed to 50% protection elicited after immunization with wild-type HSV-1 (F); and (4) latent virus was not detected at a higher rate in animals immunized and subsequently challenged with E377-MB than in immunized animals alone. These data suggest that conditionally replicating, cytokine-expressing HSV are able to elicit protective immune responses while retaining safety in an experimental murine model. |
| معلومات مُعتمدة: | P01 CA071933 United States CA NCI NIH HHS; N01-AI-65290 United States AI NIAID NIH HHS; P01-CA-71933 United States CA NCI NIH HHS; R21-AI-44300 United States AI NIAID NIH HHS |
| المشرفين على المادة: | 0 (Herpes Simplex Virus Vaccines) 0 (Vaccines, Attenuated) 0 (Vaccines, Synthetic) 187348-17-0 (Interleukin-12) 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) |
| تواريخ الأحداث: | Date Created: 20051026 Date Completed: 20060512 Latest Revision: 20161019 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.vaccine.2005.09.051 |
| PMID: | 16243413 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0264-410X |
|---|---|
| DOI: | 10.1016/j.vaccine.2005.09.051 |